A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma.

Publication Type:

Journal Article

Authors:

Hussain, Maha; Daignault, Stephanie; Agarwal, Neeraj; Grivas, Petros D; Siefker-Radtke, Arlene O; Puzanov, Igor; Macvicar, Gary R; Levine, Ellis Glenn; Srinivas, Sandy; Twardowski, Przemyslaw; Eisenberger, Mario A; Quinn, David I; Vaishampayan, Ulka N; Yu, Evan Y; Dawsey, Scott; Day, Kathleen C; Day, Mark L; Al-Hawary, Mahmoud; Smith, David C

Source:

Cancer (2014)

Keywords:

2014, Clinical Research Division, May 2014

Abstract:

Epidermal growth factor receptor overexpression is associated with poor outcomes in urothelial carcinoma (UC). Cetuximab (CTX) exhibited an antitumor effect in in vivo UC models. The efficacy of gemcitabine/cisplatin (GC) with or without CTX in patients with advanced UC was evaluated.